Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(10 sites) Australia
Border Medical oncology - Albury Wodonga Regional Cancer Centre, Albury, New South Wales Macquarie University Hospital - Oncology Department, Macquarie Park, New South Wales Peninsula and Southeast Oncology, Frankston, Victoria Denmark
Rigshospitalet - Kræftbehandling, Copenhagen, Capital Region Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica, Rome, Lazio Gruppo Humanitas - Humanitas Research Hospital - Cancer Center, Rozzano Spain
Institut Catala D'oncologia | Hospitalet | Oncologia, L'Hospitalet de Llobregat, Barcelona Hospital Universitari Vall D Hebron | Oncologia, Barcelona United Kingdom
The Christie NHS Foundation Trust - Christie Hospital, Manchester, Greater Manchester The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton, Sutton, Surrey